Education
About Us
Working with TipRanks
Follow Us
Immunitybio Inc (IBRX)
:IBRX
IBRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.28 - $10.53
Previous CloseN/A
Volume1.20M
Average Volume (3M)6.41M
Market Cap
$2.53B
Enterprise Value$2.52B
Total Cash (Recent Filing)$175.91M
Total Debt (Recent Filing)$2.47M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
May 08, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding853,442,140
10 Day Avg. Volume6,820,721
30 Day Avg. Volume6,407,410
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)156.86
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit171.00
Enterprise Value/Ebitda-9.54
Forecast
1Y Price Target
$6.08Price Target Upside104.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
ImmunityBio News
PremiumCompany Announcements
ImmunityBio’s Sales Surge Amid Strategic Advances
---
Bulls Say, Bears Say
Bulls Say
FDA AuthorizationImmunityBio received FDA authorization for an Expanded Access Program to distribute recombinant BCG, addressing U.S. shortages.
Product EfficacyANKTIVA is approved for BCG-unresponsive non-muscle invasive bladder cancer with a high 62% complete response rate and long durability of response.
Strategic PartnershipsImmunityBio's exclusive collaboration with the Serum Institute of India to develop a recombinant BCG alternative offers a strategic advantage amid a BCG shortage.
Bears Say
Clinical RisksRisks to achieving price targets include clinical risk where ImmunityBio’s assets may fail to demonstrate meaningful levels of efficacy in clinical trials.
Product VariabilityBCG is an old and genetically unstable therapy susceptible to drift, leading to costly batch-to-batch variability.
---
Ownership Overview
76.66% Insiders
2.65% Mutual Funds
2.22% Other Institutional Investors
14.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IBRX FAQ
What was Immunitybio Inc’s price range in the past 12 months?
Immunitybio Inc lowest stock price was $2.28 and its highest was $10.53 in the past 12 months.
What is Immunitybio Inc’s market cap?
Immunitybio Inc’s market cap is $2.53B.
When is Immunitybio Inc’s upcoming earnings report date?
Immunitybio Inc’s upcoming earnings report date is May 08, 2025 which is in 34 days.
How were Immunitybio Inc’s earnings last quarter?
Immunitybio Inc released its earnings results on Mar 03, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.11.
Is Immunitybio Inc overvalued?
According to Wall Street analysts Immunitybio Inc’s price is currently Undervalued.
Does Immunitybio Inc pay dividends?
Immunitybio Inc does not currently pay dividends.
What is Immunitybio Inc’s EPS estimate?
Immunitybio Inc’s EPS estimate is -0.13.
How many shares outstanding does Immunitybio Inc have?
Immunitybio Inc has 853,442,140 shares outstanding.
What happened to Immunitybio Inc’s price movement after its last earnings report?
Immunitybio Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -13.374%.
Which hedge fund is a major shareholder of Immunitybio Inc?
Currently, no hedge funds are holding shares in IBRX
---
ImmunityBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.08 (104.71% Upside)
$6.08 (104.71% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $230.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.98%
12-Months-Change
Fundamentals
Return on Equity
78.99%
Trailing 12-Months
Asset Growth
-24.09%
Trailing 12-Months
Company Description
Immunitybio Inc
ImmunityBio (IBRX) is a biotechnology company focused on developing next-generation immunotherapies and vaccines to treat cancer and infectious diseases. The company operates in the biotechnology and pharmaceutical sectors, leveraging its proprietary technology platforms to develop a diverse pipeline of therapeutic candidates. Core products include experimental treatments designed to enhance the immune system's ability to fight diseases such as cancer, HIV, and COVID-19.
---
IBRX Stock 12 Month Forecast
Average Price Target
$6.08
▲(104.71% Upside)
Technical Analysis
Crispr Therapeutics AG
―
Amneal Pharmaceuticals
―
Immunovant
―
MoonLake Immunotherapeutics
―
Edgewise Therapeutics
―
Best Analysts Covering IBRX
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
+19.88%
reiterated a buy rating 8 months ago
Copying Kelly Shi's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of +19.88% per trade.
---